<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516307</url>
  </required_header>
  <id_info>
    <org_study_id>OPT-822-001</org_study_id>
    <nct_id>NCT01516307</nct_id>
  </id_info>
  <brief_title>Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects</brief_title>
  <official_title>A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OBI Pharma, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OBI Pharma, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in
      combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects
      with stable disease or response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Progression or up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">349</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OPT-822/OPT-821 (30 μg/100 μg) +Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphate Buffer Saline (PBS) + Cyclophosphamide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPT-822/OPT-821(30 μg/100 μg) + Cyclophosphamide</intervention_name>
    <description>Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.</description>
    <arm_group_label>OPT-822/OPT-821 (30 μg/100 μg) +Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Phosphate Buffer Saline (PBS) + Cyclophosphamide</intervention_name>
    <description>Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.</description>
    <arm_group_label>Phosphate Buffer Saline (PBS) + Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects ≥ 21 years of age with histological or cytological diagnosis of breast
             carcinoma.

          -  Subjects with metastatic breast cancer who have achieved stable disease (SD), partial
             response (PR), or complete response (CR) after at least 1 regimen of anticancer
             therapy (i.e. chemotherapy or target therapy, either alone or in any combination).
             Involvement of supraclavicular lymph node is considered metastasis.

          -  Subjects must have recovered from toxicities of prior therapies. (i.e. CTCAE ≤ grade
             2).

          -  Performance status: ECOG ≤ 1 and life expectancy ≥ 3 months.

          -  Organ Function Requirements - Subjects must have adequate organ functions as defined
             below:

               -  AST/ALT ≤ 3X ULN (upper limit of normal)

               -  AST/ALT ≤ 5X ULN [with underlying Liver Metastasis]

               -  Total Bilirubin ≤ 2.0 X ULN

               -  Serum Creatinine ≤ 1.5X ULN

               -  ANC ≥ 1500 /μL

               -  Platelets &gt; 100,000/μL

               -  No Symptomatic Congestive Heart Failure (Ejection Fraction EF ≥ 50%)

          -  Ability to understand and the willingness to sign a written informed consent document
             according to institutional guidelines.

          -  All positive or negative ER (estrogen receptor), PR (progesterone receptor), and HER-2
             subjects are eligible for this study.

          -  However, subjects who are HER-2 positive and responsive to anti-HER-2 therapy (e.g.
             Herceptin), are encouraged to remain on anti-HER-2 therapy and not enroll in this
             trial.

          -  Subjects who desire to enroll in this study and for whom anti-HER-2 therapy is not
             available or contraindicated, may be eligible to enroll in this trial.

          -  In countries where continuous anti-HER2 therapy is considered standard of care for
             HER-2 positive metastatic disease, HER-2 positive subjects are not eligible.

          -  Women of childbearing potential must be willing to implement adequate contraception
             during the study. An adequate method of contraception will be at the investigator's
             discretion.

        Exclusion Criteria:

          -  Subjects are pregnant or breast-feeding at entry.

          -  Subjects with more than 2 events of disease progression after the development of
             metastatic breast cancer.

          -  Subjects who are currently receiving any other concomitant anticancer therapy with the
             EXCEPTION of bisphosphonates and hormone therapy.

               -  During the study period, subjects using hormonal therapy and bisphosphonates
                  should maintain a constant dose and should not change existing regimen.

               -  However, if a change in hormonal therapy is indicated, e.g. due to intolerable
                  adverse effects, the regimen may be modified but change should be minimized
                  thereafter.

          -  Subjects with metastasis limited to the bone only are excluded. However, subjects with
             current metastasis limited to the bone only and with a history of distant metastasis
             are eligible. Subjects with current metastasis limited to the bone only and with
             current breast tissue lesion are eligible.

          -  Subjects who have any history of other malignancy (except non-melanoma skin carcinoma
             and carcinoma-in-situ of the uterine cervix) within 5 years of study entry.

          -  Subjects with splenectomy.

          -  Subjects with HIV infection.

          -  Subjects with any major autoimmune diseases or autoimmune disorders requiring systemic
             iv/oral steroids or immunosuppressive or immunomodulatory therapies.

               -  e.g. Type 1 juvenile onset diabetes mellitus, antibody positive for rheumatoid
                  arthritis, Grave's disease, Hashimoto's thyroiditis, lupus, scleroderma, systemic
                  vasculitis, hemolytic anemia, immune mediated thrombocytopenia, etc

               -  Autoimmune disorders confined to the skin (e.g. psoriasis) are eligible, and
                  topical steroids are allowed for the treatment of such skin disorders.

          -  Subjects with any known uncontrolled inter-current illness including ongoing or active
             infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Subjects with any of the following MEDICATIONS within 4 weeks prior to randomization:

               -  Anti-neoplastic agents

               -  Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)]

               -  Immunosuppressants (e.g. Cyclosporin, Rapamycin, Tacrolimus, Rituximab,
                  Alemtuzumab, Natalizumab, etc.).

               -  Another investigational drug

          -  Subjects with pleural effusions and/or ascites, due to malignancy, requiring
             paracentesis every 2 weeks or more frequently.

          -  Subjects with any known severe allergies (e.g. anaphylaxis) to any active or inactive
             ingredients in the study drugs.

          -  Subjects with bladder inflammation and urinary outflow obstruction.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine (UCI)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Integrative Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Women's Cancer Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIMED Medical Institute</name>
      <address>
        <city>Hong-Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCG, Bangalore Institute of Oncology</name>
      <address>
        <city>Bengaluru</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Manavata Cancer Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Chungcheongbuk-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Chungcheongbuk-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ,</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-KS</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital -Linkou</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shuang-Ho Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <disposition_first_submitted>March 2, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 3, 2017</disposition_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

